Zai Lab Ltd- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Zai Lab Ltd 公司

再鼎醫藥是一家主要從事生物製藥的控股公司。公司致力於通過產品發現、開發和商業化來解決腫瘤、自身免疫性疾病、感染性疾病和中樞神經系統疾病領域尚未滿足的醫療需求。公司擁有一系列從發現階段到後期臨牀項目的專利候選藥物。其中包括 ZEJULA、OPTUNE、QINLOCK、NUZYRA 和 VYVGART 等。

Zai Lab Ltd簡介



公司代碼ZLAB

公司名稱Zai Lab Ltd

上市日期Sep 28, 2020

CEODr. Ying (Samantha) Du, Ph.D.

員工數量1869

證券類型Depository Receipt

年結日Sep 28

公司地址Building B, 899 Halei Road, Pudong

城市SHANGHAI

上市交易所NASDAQ Global Market Consolidated

國家China

郵編201203

電話862161632588

網址https://www.zailaboratory.com/

公司代碼ZLAB

上市日期Sep 28, 2020

CEODr. Ying (Samantha) Du, Ph.D.

Zai Lab Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+12.18%

Mr. Joshua L. Smiley

President, Chief Operating Officer

86.60K

+13.05%

Mr. William David (Bill) Lis

Independent Director

35.11K

-7.83%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

17.44K

-1.36%

Mr. Leon Oliver (Lonnie) Moulder, Jr.

Independent Director

--

Mr. Michel Pericles Vounatsos

Independent Director

--

Dr. Richard B. Gaynor, M.D.

Independent Director

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

Mr. Peter Karl Wirth, J.D.

Independent Director

--

Ms. Christine Chiou

Senior Vice President, Head - Investor Relations

--

名稱

名稱/職務

職務

持股

持股變動

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+12.18%

Mr. Joshua L. Smiley

President, Chief Operating Officer

86.60K

+13.05%

Mr. William David (Bill) Lis

Independent Director

35.11K

-7.83%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

17.44K

-1.36%

Mr. Leon Oliver (Lonnie) Moulder, Jr.

Independent Director

--

Mr. Michel Pericles Vounatsos

Independent Director

--

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

業務USD

名稱

營收

佔比

ZEJULA

41.04M

37.62%

VYVGART

26.50M

24.29%

NUZYRA

14.29M

13.10%

Optune

12.36M

11.33%

QINLOCK

8.54M

7.83%

其他

6.36M

5.83%

地區USD

名稱

營收

佔比

China (Mainland)

109.98M

0.00%

業務

地區

業務USD

名稱

營收

佔比

ZEJULA

41.04M

37.62%

VYVGART

26.50M

24.29%

NUZYRA

14.29M

13.10%

Optune

12.36M

11.33%

QINLOCK

8.54M

7.83%

其他

6.36M

5.83%

股東統計

更新時間: 10月31日週五

持股股東

股東類型

持股股東

佔比

Capital World Investors

5.40%

RTW Investments L.P.

4.95%

Fidelity Management & Research Company LLC

4.37%

ClearBridge Investments, LLC

3.59%

Janus Henderson Investors

1.97%

其他

79.72%

持股股東

佔比

Capital World Investors

5.40%

RTW Investments L.P.

4.95%

Fidelity Management & Research Company LLC

4.37%

ClearBridge Investments, LLC

3.59%

Janus Henderson Investors

1.97%

其他

79.72%

股東類型

持股股東

佔比

Investment Advisor

16.30%

Investment Advisor/Hedge Fund

16.01%

Hedge Fund

5.50%

Individual Investor

1.74%

Private Equity

1.38%

Venture Capital

1.13%

Research Firm

0.90%

Pension Fund

0.44%

Sovereign Wealth Fund

0.18%

其他

56.42%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

372

46.61M

41.70%

-15.37M

2025Q2

394

60.58M

54.15%

-11.96M

2025Q1

453

59.51M

53.68%

-14.18M

2024Q4

446

60.80M

55.47%

-4.29M

2024Q3

439

51.45M

51.99%

-10.14M

2024Q2

454

47.04M

47.66%

-14.67M

2024Q1

465

46.22M

46.47%

-13.77M

2023Q4

497

46.31M

46.92%

-16.57M

2023Q3

537

44.27M

45.68%

-20.42M

2023Q2

568

47.21M

48.74%

-23.76M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

6.04M

5.4%

+27.77K

+0.46%

Jun 30, 2025

RTW Investments L.P.

5.54M

4.95%

+2.40M

+76.52%

Jun 30, 2025

Fidelity Management & Research Company LLC

4.89M

4.37%

+206.80K

+4.42%

Jun 30, 2025

ClearBridge Investments, LLC

4.01M

3.59%

+732.39K

+22.33%

Jun 30, 2025

Janus Henderson Investors

2.20M

1.97%

-1.62M

-42.37%

Jun 30, 2025

Baron Capital Management, Inc.

1.59M

1.42%

-241.68K

-13.21%

Jun 30, 2025

Segantii Capital Management Limited

1.56M

1.39%

-131.64K

-7.80%

Mar 31, 2024

Wellington Management Company, LLP

1.38M

1.23%

-2.27M

-62.25%

Jun 30, 2025

Fidelity Institutional Asset Management

1.31M

1.17%

-387.51K

-22.82%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

1.31M

1.17%

+958.14K

+273.75%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

Tema Oncology ETF

2.64%

ALPS Medical Breakthroughs ETF

2.2%

Virtus LifeSci Biotech Products ETF

1.31%

Invesco Golden Dragon China ETF

0.84%

National Security Emerging Markets Index ETF

0.46%

iShares Biotechnology ETF

0.25%

Capital Group New Geography Equity ETF

0.18%

ProShares Ultra Nasdaq Biotechnology

0.17%

Invesco Nasdaq Biotechnology ETF

0.16%

ActivePassive International Equity ETF

0.04%

Tema Oncology ETF

佔比2.64%

ALPS Medical Breakthroughs ETF

佔比2.2%

Virtus LifeSci Biotech Products ETF

佔比1.31%

Invesco Golden Dragon China ETF

佔比0.84%

National Security Emerging Markets Index ETF

佔比0.46%

iShares Biotechnology ETF

佔比0.25%

Capital Group New Geography Equity ETF

佔比0.18%

ProShares Ultra Nasdaq Biotechnology

佔比0.17%

Invesco Nasdaq Biotechnology ETF

佔比0.16%

ActivePassive International Equity ETF

佔比0.04%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據